Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avonex in Chinese Subjects With Relapsing Multiple Sclerosis
NCT01181115Phase 3Completed
- Sponsor
- Biogen
- Start
- Apr 2010
- Primary completion
- Oct 2011
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of interferon beta-1a in multiple sclerosis (MS), sponsored by Biogen. Primary endpoints: Number and proportion of subjects with adverse events at 24 weeks, Assessment of clinical laboratory parameters at 24 weeks and 7 more. Started Apr 2010; status: completed.
02
Drugs
interferon beta-1a
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT01181115.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01181115.